Theragen Etex Statistics

Total Valuation

Theragen Etex has a market cap or net worth of KRW 110.78 billion. The enterprise value is 155.48 billion.

Market Cap	110.78B
Enterprise Value	155.48B

Important Dates

The next estimated earnings date is Thursday, May 15, 2025.

Earnings Date	May 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Theragen Etex has 36.68 million shares outstanding.

Current Share Class	36.68M
Shares Outstanding	36.68M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	31.10%
Owned by Institutions (%)	0.93%
Float	22.77M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.44
PB Ratio	0.85
P/TBV Ratio	1.04
P/FCF Ratio	n/a
P/OCF Ratio	61.96
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.63, with an EV/FCF ratio of -16.19.

EV / Earnings	-3.79
EV / Sales	0.62
EV / EBITDA	6.63
EV / EBIT	8.97
EV / FCF	-16.19

Financial Position

The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.39.

Current Ratio	1.28
Quick Ratio	0.88
Debt / Equity	0.39
Debt / EBITDA	2.84
Debt / FCF	-5.26
Interest Coverage	4.35

Financial Efficiency

Return on equity (ROE) is -28.32% and return on invested capital (ROIC) is 3.93%.

Return on Equity (ROE)	-28.32%
Return on Assets (ROA)	3.03%
Return on Invested Capital (ROIC)	3.93%
Return on Capital Employed (ROCE)	8.53%
Revenue Per Employee	1.24B
Profits Per Employee	-202.90M
Employee Count	202
Asset Turnover	1.04
Inventory Turnover	4.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.25% in the last 52 weeks. The beta is 0.24, so Theragen Etex's price volatility has been lower than the market average.

Beta (5Y)	0.24
52-Week Price Change	-24.25%
50-Day Moving Average	3,018.20
200-Day Moving Average	3,313.53
Relative Strength Index (RSI)	53.32
Average Volume (20 Days)	50,965

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Theragen Etex had revenue of KRW 249.63 billion and -40.98 billion in losses. Loss per share was -1,280.56.

Revenue	249.63B
Gross Profit	125.51B
Operating Income	11.65B
Pretax Income	-43.16B
Net Income	-40.98B
EBITDA	17.74B
EBIT	11.65B
Loss Per Share	-1,280.56

Full Income Statement

Balance Sheet

The company has 24.18 billion in cash and 50.48 billion in debt, giving a net cash position of -26.29 billion or -716.76 per share.

Cash & Cash Equivalents	24.18B
Total Debt	50.48B
Net Cash	-26.29B
Net Cash Per Share	-716.76
Equity (Book Value)	130.54B
Book Value Per Share	3,503.98
Working Capital	28.43B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.79 billion and capital expenditures -11.39 billion, giving a free cash flow of -9.60 billion.

Operating Cash Flow	1.79B
Capital Expenditures	-11.39B
Free Cash Flow	-9.60B
FCF Per Share	-261.80

Full Cash Flow Statement

Margins

Gross margin is 50.28%, with operating and profit margins of 4.67% and -16.42%.

Gross Margin	50.28%
Operating Margin	4.67%
Pretax Margin	-17.29%
Profit Margin	-16.42%
EBITDA Margin	7.11%
EBIT Margin	4.67%
FCF Margin	n/a

Dividends & Yields

Theragen Etex does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-37.00%
FCF Yield	-8.67%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Theragen Etex has an Altman Z-Score of 1.98. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.98
Piotroski F-Score	n/a